Matthew Claster

Matthew Claster serves as Chief Business Officer at Clarapath. Clarapath operates in the medical devices sector with approximately 67.0 employees. The company is headquartered in New York, New York. Clarapath generates annual revenue of 2300000.0. To date, Clarapath has raised 67424620.0 in total funding, with the most recent round being Series B.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 6,952 executive contacts are available in New York.
• • Our database includes 201,468 c suite-level executives.

Gmail Google Apps GoDaddy Hosting Atlassian Cloud Hubspot Remote AI

automated sectioning histopathology tissue processing lab services microtomy technology digital pathology clinical diagnostics anatomic pathology quality control slide production lab automation pathology workflow turnaround time reliability data hosting data analytics machine learning optics systems embedded tissue processing cloud-based solutions image analysis whole slide imaging h&e staining ihc staining high-resolution images observational methodologies specimen management pathology research cro services clinical applications data compliance quality assurance tissue sample preparation productivity enhancement automated workflow 38 µm sectioning batch processing error reduction pathologist support database integration real-time monitoring sample tracking paraffin embedding live imaging data mining cost reduction capacity augmentation artificial intelligence information technology & services enterprise software enterprises computer software b2b

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Matthew Claster in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Clarapath.

Matthew Claster's Position in the MessageCEO Database

• •Matthew Claster is 1 of 1 verified executive contact we track at Clarapath.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •6,778 verified executive contacts in New York are in the database.
• •7 verified contacts work at medical devices companies in the 67.0 employee range (same size as Clarapath).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Matthew Claster directly?

Matthew Claster's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Business Officer at Clarapath. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Matthew Claster work for?

Matthew Claster is Chief Business Officer at Clarapath, a company in the medical devices sector with 67.0 employees. The company is based in New York, New York.

Can I pitch or sell to Matthew Claster?

As Chief Business Officer at Clarapath, Matthew Claster is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Matthew Claster directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Matthew Claster in?

Matthew Claster works in the medical devices industry as Chief Business Officer at Clarapath. MessageCEO provides verified contact information for executives across all major industries.

Is Matthew Claster's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Matthew Claster's profile is kept up-to-date with the latest available information.

Last updated: July 30, 2026